Seeking Alpha
 

Johnson & Johnson (JNJ)

- NYSE
  • Oct. 18, 2011, 7:49 AM
    Johnson & Johnson (JNJ): Q3 EPS of $1.24 beats by $0.03. Revenue of $16B (+6.8% Y/Y) misses by $20M. Sees FY11 EPS of $4.95-5.00 as against consensus of $4.96. Shares -1.4% premarket. (PR)
    | Comment!
  • Oct. 18, 2011, 12:05 AM
    Notable earnings before Tuesday's open: BAC, CHKP, DPZ, EDU, EMC, FRX, GPC, GS, HOG, JNJ, KO, OMC, PH, PII, STT, UNH
    | Comment!
  • Sep. 30, 2011, 10:31 AM
    Merck (MRK) stands as the biggest gainer in the Dow, up 1.2%, after strategically freeing itself up to offer more over-the-counter drugs by selling its interest in a joint venture with Johnson & Johnson (JNJ +0.2%).
    | Comment!
  • Sep. 28, 2011, 4:33 PM
    Merck (MRK) sells its 50% interest in an over-the-counter drug joint venture with Johnson & Johnson (JNJ) to J&J unit McNeil PPC. Merck says it will get a one-time payment of $175M plus more freedom to convert its prescription products to over-the-counter versions. (PR)
    | Comment!
  • Sep. 28, 2011, 3:42 PM
    Johnson & Johnson (JNJ -0.6%) outperforms the general market today after saying Ethicon Endo-Surgery, one of its subsidiaries, agrees to buy privately held SterilMed for an undisclosed sum.
    | Comment!
  • Sep. 26, 2011, 10:27 AM
    Johnson & Johnson (JNJ +1.2%) is trading higher this morning after the FDA put its stamp of approval over the weekend for using company's blockbuster drug Remicade on pediatric patients with ulcerative colitis.
    | Comment!
  • Sep. 23, 2011, 10:46 AM
    Yet another recall by Johnson & Johnson (JNJ -0.9%), this time for ~200,000 syringes of its Eprex anemia drug in the U.K., Canada and 15 other countries after internal testing revealed some batches of the drug were less potent than necessary. A string of recalls has cost JNJ an estimated $1.9B in lost sales during 2010-11.
    | Comment!
  • Sep. 22, 2011, 11:50 AM
    UBS' latest list of its clients' 15 most shorted stocks: FSLR, GCI, NFLX, CTRP, CIEN, JCP, GRMN, GMCR, BBY, FTR, CRM, GM, C, BAC, JNJ.
    | 4 Comments
  • Sep. 22, 2011, 8:58 AM
    Johnson & Johnson (JNJ) has begun to ship new Tylenol Cold & Flu Severe caplets, among the first medications it has shipped since a series of high-profile recalls that cost the company $900M in lost sales in 2010; analysts have estimated the recalls will cost $1B this year. JNJ -2.3% premarket.
    | Comment!
  • Sep. 14, 2011, 9:12 PM
    Johnson & Johnson (JNJ) must face a trial in Arkansas over claims the company hid the risks of its anti-psychotic drug Risperdal, when selling it to residents covered by the state's Medicaid program. Shares flat AH.
    | Comment!
  • Sep. 13, 2011, 5:40 PM
    Boston Scientific (BSX) names Michael Mahoney to replace current CEO Ray Elliott who is stepping down on October 17. However, Mahoney will not assume the position until November due to "post-employment obligations" to Johnson & Johnson (JNJ). Hank Kucheman, VP of the cardiology, rhythm and vascular group, will serve as interim CEO. Shares -0.2% AH.
    | Comment!
  • Sep. 9, 2011, 8:22 AM
    The Senate has approved a major overhaul of U.S. patent law, one that will lead to patents being granted to the first company to file for an invention, rather than the first to invent it. Major tech and drug companies such as MSFT, IBM, JNJ, and LLY support the bill, but an association of small businesses opposes it.
    | 4 Comments
  • Sep. 8, 2011, 5:19 PM
    An FDA advisory committee votes 9- 2, with one abstention, to approve the anticoagulant drug Xarelto manufactured jointly by Johnson & Johnson (JNJ) and Bayer AG (BAYRY.PK). JNJ +0.6%, BAYRY.PK -0.1% AH.
    | Comment!
  • Sep. 7, 2011, 11:46 AM
    European drug regulators approve Johnson & Johnson's (JNJ +0.6%) prostate cancer treatment Zytiga for men whose disease has progressed after chemotherapy. Wall Street expects the worldwide market for prostate cancer therapies, now approaching $1B, to grow to $5B by 2015 as a result of the influx of new treatments.
    | Comment!
  • Sep. 6, 2011, 1:35 PM
    UBS is out with its latest list of 15 most shorted stocks based on the highest concentration of its clients, and it includes some blue-chippers: AMZN, JCP, GMCR, ESRX, PBI, CRM, FTR, ECL, BXP, SLG, UA, VZ, JNJ, GS, IBM.
    | 2 Comments
  • Sep. 6, 2011, 12:08 PM
    German drug maker Bayer (BAYRY.PK -12%) takes a hit this morning after Xarelto, the drug it's co-developing with Johnson & Johnson (JNJ -0.5%) was rejected by FDA scientists.
    | Comment!
JNJ vs. ETF Alternatives
Company Description
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the health care field within its Consumer, Pharmaceutical and Medical Devices, and Diagnostics business segments.